BDBM698822 (2-((1- ((dimethylamino)methyl)cyclopropyl) methoxy)-4-(4-fluoroazepan-1-yl)-5,7- dihydro-6H-pyrrolo[3,4-d]pyrimidin-6- yl)(3-hydroxy-8-iodonaphthalen-1- yl)methanone::US20240317759, Example 32

SMILES CN1CCN(C2CCN(c3ccc(Nc4nc(NC5CC5)c(-c5cccc6[nH]ccc56)nc4C(N)=O)cc3)CC2)CC1

InChI Key InChIKey=VRDOZGVIZDCMES-UHFFFAOYSA-N

Data  6 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 698822   

TargetEpidermal growth factor receptor(Human)
Wigen Biomedicine Technology (Shanghai) Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 698822BDBM698822(US12600714, Compound 522)
Affinity DataIC50: 0.220nMAssay Description:JAK1, JAK2, JAK3 and Tyk2 were purchased from Carna Biosciences, Inc. As the substrate, LANCE Ultra ULight-JAK1 Peptide (manufactured by PerkinElmer ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/24/2026
Entry Details
US Patent